This is a prospective, interventional, exploratory, four-arm - dose response study, comparative, double-blind, randomized, placebo-control, proof of concept, safety, efficacy and in-use tolerability study of three different dosage formulation of test hair growth products and placebo in patients with mild to moderate Androgenic Alopecia (Grade I to III).
Age: 25 to 45 years and above (both inclusive) at the time of consent.
Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
Females of childbearing potential must have a self-reported negative urine pregnancy.
Patient is in good general health as determined by the Investigator on the basis of medical history.
Patient have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems.
Patient have history of any dermatological condition of the scalp other than hair loss and dandruff.
Patient have history of any prior hair growth procedures (e.g. hair transplant or laser).
Patient who had taken topical treatment of hair loss for at least 4 weeks.
NovoBliss Research Pvt Ltd
Lead sponsor
Zywie Ventures Privated Ltd
Collaborator